# XYLYX BIO, INC.: Liver fibrosis cell-based assay platform: integrating patient-derived fibrotic liver ECM with primary stellate cells, Kupffer cells, and hepatocytes to accelerate anti-fibrotic drug development

**Lab Budget Score:** 55/100

| Field | Value |
|---|---|
| Organization | XYLYX BIO, INC. |
| Location | BROOKLYN, NY |
| Project | Liver fibrosis cell-based assay platform: integrating patient-derived fibrotic liver ECM with primary stellate cells, Kupffer cells, and hepatocytes to accelerate anti-fibrotic drug development |
| Project number | 5R44DK139877-03 |
| Mechanism | R44 |
| Institute | National Institute of Diabetes and Digestive and Kidney Diseases |
| Award | $956,566 |
| Awarded | 2026-09-10 |
| Project period | 2024-09-01 to 2027-08-31 |
| UEI | N2N9KL2Y52X1 |

## Why this score
- Award of $400K or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11413845). Last refreshed: 2026-11-03T18:16:24.961Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.